Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies
March 2, 2022 8:08 AM ESTJefferies analyst Andrew Tsai raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $90.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "Q4 Caplyta sales in mostly schizophrenia (SCZ) grew by +18% Q/Q to $25.5M (in line vs cons;... More
